NCT05626348View on ClinicalTrials.gov

The Clinical Efficacy of Immunomodulators in RA Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2026

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Iguratimod

Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

DRUG

Methotrexate

Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

DRUG

Adalimumab Injection

Adalimumab Injection，40mg，iH，every two weeks (q2w) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

DRUG

Leflunomide

Leflunomide，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

DRUG

Hydroxychloroquine

Hydroxychloroquine，200mg, po, twice per day (bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.

Trial Locations (1)

250012

RECRUITING

Qilu Hospital, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER

NCT05626348 - The Clinical Efficacy of Immunomodulators in RA Patients | Biotech Hunter | Biotech Hunter